Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Pediatric B cell acute leukemia: limiting bone toxicity and defining the bone microenvironment
EF 2017-18
Résumé
Nearly 90% of children diagnosed with B cell acute leukemia (B-ALL) can be cured with current intensive multi-agent chemotherapy, however, many of the survivors must endure chronic late effects of the disease and its' treatment, including osteoporosis and osteonecrosis. Fractures are a major complication of pediatric leukemia at diagnosis, during and after treatment. The current project will focus to understand how these leukemia cells in the bone marrow interact with the surrounding bone, in order to improve clinical interventions to limit bone destruction in patients. The first part of the project involves investigating a compound known to inhibit bone destruction. The goal is to complete a pre-clinical study to determine if this compound can protect the bones of leukemia patients receiving chemotherapy, while not affecting the efficacy of the anti-cancer therapy itself. The second part of the project will investigate how the leukemia cells specifically interact with the surrounding bone and how this can mediate bone destruction, leading to osteoporosis and osteonecrosis. To do this, we will investigate the genes being expressed by the leukemia cells and the surrounding bone tissue, as well as use high-resolution imaging to visualize this region. These studies will provide a deep, comprehensive characterization of leukemia biology within the bone marrow to provide evidence to support using bone protective drugs in children undergoing leukemia treatment. The goal is to further improve therapy so that children cured of B-ALL can avoid the after effects of the disease, and improve their quality of life.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
386507
Name
MacDonald Alannah
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Pediatric B cell acute leukemia: limiting bone toxicity and defining the bone microenvironment
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bone Microenvironment; Bone Protection; Gene Expression; Imaging; Leukemia; Mouse Models; Osteoporosis; Patient Derived Xenografts; Pediatric Cancer; Pre-Clinical
Abstract
Nearly 90% of children diagnosed with B cell acute leukemia (B-ALL) can be cured with current intensive multi-agent chemotherapy, however, many of the survivors must endure chronic late effects of the disease and its' treatment, including osteoporosis and osteonecrosis. Fractures are a major complication of pediatric leukemia at diagnosis, during and after treatment. The current project will focus to understand how these leukemia cells in the bone marrow interact with the surrounding bone, in order to improve clinical interventions to limit bone destruction in patients. The first part of the project involves investigating a compound known to inhibit bone destruction. The goal is to complete a pre-clinical study to determine if this compound can protect the bones of leukemia patients receiving chemotherapy, while not affecting the efficacy of the anti-cancer therapy itself. The second part of the project will investigate how the leukemia cells specifically interact with the surrounding bone and how this can mediate bone destruction, leading to osteoporosis and osteonecrosis. To do this, we will investigate the genes being expressed by the leukemia cells and the surrounding bone tissue, as well as use high-resolution imaging to visualize this region. These studies will provide a deep, comprehensive characterization of leukemia biology within the bone marrow to provide evidence to support using bone protective drugs in children undergoing leukemia treatment. The goal is to further improve therapy so that children cured of B-ALL can avoid the after effects of the disease, and improve their quality of life.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
MacDonald, Alannah
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~